ProMIS Neurosciences Inc (PMN)
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
📈 **POSITIVE** • High confidence analysis (90%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical